|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: PHLPP2 |
Gene summary for PHLPP2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | PHLPP2 | Gene ID | 23035 |
| Gene name | PH domain and leucine rich repeat protein phosphatase 2 | |
| Gene Alias | PHLPPL | |
| Cytomap | 16q22.2 | |
| Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | Q6ZVD8 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 23035 | PHLPP2 | HTA11_3410_2000001011 | Human | Colorectum | AD | 2.74e-08 | -4.52e-01 | 0.0155 |
| 23035 | PHLPP2 | HTA11_347_2000001011 | Human | Colorectum | AD | 5.57e-04 | 4.81e-01 | -0.1954 |
| 23035 | PHLPP2 | HTA11_866_3004761011 | Human | Colorectum | AD | 1.46e-07 | -4.59e-01 | 0.096 |
| 23035 | PHLPP2 | HTA11_7696_3000711011 | Human | Colorectum | AD | 2.26e-06 | -3.74e-01 | 0.0674 |
| 23035 | PHLPP2 | HTA11_6818_2000001021 | Human | Colorectum | AD | 1.42e-02 | -4.31e-01 | 0.0588 |
| 23035 | PHLPP2 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 2.15e-12 | -4.03e-01 | 0.294 |
| 23035 | PHLPP2 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 1.21e-11 | -4.68e-01 | 0.3005 |
| 23035 | PHLPP2 | F007 | Human | Colorectum | FAP | 6.83e-05 | -4.42e-01 | 0.1176 |
| 23035 | PHLPP2 | A002-C-010 | Human | Colorectum | FAP | 6.45e-07 | -3.25e-01 | 0.242 |
| 23035 | PHLPP2 | A001-C-207 | Human | Colorectum | FAP | 1.32e-05 | -3.78e-01 | 0.1278 |
| 23035 | PHLPP2 | A015-C-203 | Human | Colorectum | FAP | 5.13e-21 | -4.43e-01 | -0.1294 |
| 23035 | PHLPP2 | A015-C-204 | Human | Colorectum | FAP | 5.83e-06 | -3.36e-01 | -0.0228 |
| 23035 | PHLPP2 | A014-C-040 | Human | Colorectum | FAP | 1.40e-04 | -5.52e-01 | -0.1184 |
| 23035 | PHLPP2 | A002-C-201 | Human | Colorectum | FAP | 8.91e-13 | -4.54e-01 | 0.0324 |
| 23035 | PHLPP2 | A002-C-203 | Human | Colorectum | FAP | 2.30e-05 | -3.28e-01 | 0.2786 |
| 23035 | PHLPP2 | A001-C-119 | Human | Colorectum | FAP | 2.11e-06 | -3.53e-01 | -0.1557 |
| 23035 | PHLPP2 | A001-C-108 | Human | Colorectum | FAP | 4.70e-16 | -4.30e-01 | -0.0272 |
| 23035 | PHLPP2 | A002-C-205 | Human | Colorectum | FAP | 9.75e-17 | -4.69e-01 | -0.1236 |
| 23035 | PHLPP2 | A001-C-104 | Human | Colorectum | FAP | 4.51e-05 | -3.17e-01 | 0.0184 |
| 23035 | PHLPP2 | A015-C-005 | Human | Colorectum | FAP | 6.19e-06 | -3.99e-01 | -0.0336 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0016311 | Colorectum | AD | dephosphorylation | 123/3918 | 417/18723 | 1.84e-05 | 3.82e-04 | 123 |
| GO:0006470 | Colorectum | AD | protein dephosphorylation | 88/3918 | 281/18723 | 2.56e-05 | 4.89e-04 | 88 |
| GO:00064702 | Colorectum | MSS | protein dephosphorylation | 73/3467 | 281/18723 | 1.15e-03 | 1.12e-02 | 73 |
| GO:00163112 | Colorectum | MSS | dephosphorylation | 101/3467 | 417/18723 | 1.98e-03 | 1.70e-02 | 101 |
| GO:00163113 | Colorectum | FAP | dephosphorylation | 95/2622 | 417/18723 | 7.07e-07 | 3.32e-05 | 95 |
| GO:00064704 | Colorectum | FAP | protein dephosphorylation | 69/2622 | 281/18723 | 1.47e-06 | 6.39e-05 | 69 |
| GO:0021543 | Colorectum | FAP | pallium development | 36/2622 | 169/18723 | 6.06e-03 | 3.81e-02 | 36 |
| GO:0030900 | Colorectum | FAP | forebrain development | 70/2622 | 379/18723 | 8.64e-03 | 4.98e-02 | 70 |
| GO:00163114 | Colorectum | CRC | dephosphorylation | 79/2078 | 417/18723 | 1.27e-06 | 7.21e-05 | 79 |
| GO:00064705 | Colorectum | CRC | protein dephosphorylation | 57/2078 | 281/18723 | 4.49e-06 | 1.87e-04 | 57 |
| GO:00309001 | Colorectum | CRC | forebrain development | 66/2078 | 379/18723 | 1.36e-04 | 2.57e-03 | 66 |
| GO:00215431 | Colorectum | CRC | pallium development | 32/2078 | 169/18723 | 1.74e-03 | 1.79e-02 | 32 |
| GO:0021537 | Colorectum | CRC | telencephalon development | 43/2078 | 248/18723 | 2.01e-03 | 2.01e-02 | 43 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa04151 | Colorectum | FAP | PI3K-Akt signaling pathway | 75/1404 | 354/8465 | 1.23e-02 | 4.19e-02 | 2.55e-02 | 75 |
| hsa041511 | Colorectum | FAP | PI3K-Akt signaling pathway | 75/1404 | 354/8465 | 1.23e-02 | 4.19e-02 | 2.55e-02 | 75 |
| hsa041512 | Colorectum | CRC | PI3K-Akt signaling pathway | 64/1091 | 354/8465 | 2.70e-03 | 1.77e-02 | 1.20e-02 | 64 |
| hsa041513 | Colorectum | CRC | PI3K-Akt signaling pathway | 64/1091 | 354/8465 | 2.70e-03 | 1.77e-02 | 1.20e-02 | 64 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| PHLPP2 | SNV | Missense_Mutation | novel | c.96T>G | p.Cys32Trp | p.C32W | Q6ZVD8 | protein_coding | deleterious(0.03) | probably_damaging(0.996) | TCGA-A2-A0YE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Taxotere | SD |
| PHLPP2 | SNV | Missense_Mutation | c.2585N>T | p.Arg862Met | p.R862M | Q6ZVD8 | protein_coding | deleterious(0) | probably_damaging(0.961) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| PHLPP2 | SNV | Missense_Mutation | c.1127N>T | p.Ser376Phe | p.S376F | Q6ZVD8 | protein_coding | deleterious(0) | possibly_damaging(0.853) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| PHLPP2 | SNV | Missense_Mutation | c.274N>C | p.Asp92His | p.D92H | Q6ZVD8 | protein_coding | deleterious(0.02) | probably_damaging(0.998) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| PHLPP2 | SNV | Missense_Mutation | c.1648N>T | p.Leu550Phe | p.L550F | Q6ZVD8 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AO-A12H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
| PHLPP2 | SNV | Missense_Mutation | rs142472702 | c.2720N>A | p.Arg907Gln | p.R907Q | Q6ZVD8 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| PHLPP2 | SNV | Missense_Mutation | rs774528822 | c.193N>A | p.Val65Ile | p.V65I | Q6ZVD8 | protein_coding | deleterious(0.02) | probably_damaging(0.979) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
| PHLPP2 | SNV | Missense_Mutation | c.3056G>A | p.Ser1019Asn | p.S1019N | Q6ZVD8 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-D8-A13Z-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine | SD | |
| PHLPP2 | SNV | Missense_Mutation | rs147433033 | c.3940G>A | p.Glu1314Lys | p.E1314K | Q6ZVD8 | protein_coding | tolerated_low_confidence(0.74) | benign(0.028) | TCGA-E2-A14V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
| PHLPP2 | SNV | Missense_Mutation | rs775586595 | c.833N>G | p.Asn278Ser | p.N278S | Q6ZVD8 | protein_coding | deleterious(0) | probably_damaging(0.985) | TCGA-EW-A1PC-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |